Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Cassier

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
The Lancet. Oncology|March 25, 2018
Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trialHans Gelderblom, Claire Cropet, Christine Chevreau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2009
A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumorsGeorge D Demetri, Paolo G Casali, Jean-Yves Blay, et al.
Cancer|January 10, 2018
Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07)Michael Montemurro, Angela Cioffi, Julien Dômont, et al.
Communications Biology|October 7, 2022
SMAD2/3 mediate oncogenic effects of TGF-β in the absence of SMAD4Adrien Bertrand-Chapel, Cassandre Caligaris, Tanguy Fenouil, et al.
BMC Cancer|November 26, 2014
The off-label use of targeted therapies in sarcomas: the OUTC'S programLauriane Eberst, Claire Cropet, Axel Le Cesne, et al.
Oncotarget|August 29, 2015
The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic valueXiaojun Jiang, Daniel Pissaloux, Christelle De La Fouchardiere, et al.
Future Oncology (London, England)|January 13, 2017
EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenibMévidette El-Madani, Olivier Colomban, Michel Tod, et al.
JCO Precision Oncology|January 20, 2022
Tumor Molecular Profiling: Pediatric Results of the ProfiLER StudySarah Benezech, Pierre Saintigny, Valery Attignon, et al.
Nature Medicine|April 8, 2025
Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trialOlivier Trédan, Damien Pouessel, Nicolas Penel, et al.
Journal for Immunotherapy of Cancer|October 24, 2020
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patientsJean-Pascal Machiels, Carlos Gomez-Roca, Jean-Marie Michot, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
The Lancet. Oncology|March 25, 2018
Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trialHans Gelderblom, Claire Cropet, Christine Chevreau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2009
A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumorsGeorge D Demetri, Paolo G Casali, Jean-Yves Blay, et al.
Cancer|January 10, 2018
Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07)Michael Montemurro, Angela Cioffi, Julien Dômont, et al.
Communications Biology|October 7, 2022
SMAD2/3 mediate oncogenic effects of TGF-β in the absence of SMAD4Adrien Bertrand-Chapel, Cassandre Caligaris, Tanguy Fenouil, et al.
BMC Cancer|November 26, 2014
The off-label use of targeted therapies in sarcomas: the OUTC'S programLauriane Eberst, Claire Cropet, Axel Le Cesne, et al.
Oncotarget|August 29, 2015
The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic valueXiaojun Jiang, Daniel Pissaloux, Christelle De La Fouchardiere, et al.
Future Oncology (London, England)|January 13, 2017
EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenibMévidette El-Madani, Olivier Colomban, Michel Tod, et al.
JCO Precision Oncology|January 20, 2022
Tumor Molecular Profiling: Pediatric Results of the ProfiLER StudySarah Benezech, Pierre Saintigny, Valery Attignon, et al.
Nature Medicine|April 8, 2025
Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trialOlivier Trédan, Damien Pouessel, Nicolas Penel, et al.
Journal for Immunotherapy of Cancer|October 24, 2020
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patientsJean-Pascal Machiels, Carlos Gomez-Roca, Jean-Marie Michot, et al.
Pageof 6